to go further
MYO Technology is superior
Traditional protein therapeutic treatments require large doses of short acting medicine. In addition to this, the costs of production and cold chain logistics are very high. Naturally, this reality makes it difficult for the population to access the necessary medication.
Make Your Own (MYO) Technology™ assumes a treatment that effectively eliminate these hurdles. At RenBio, the logistics of cold chain management and long, costly, manufacturing processes will not affect you.
Our treatment regimens are long-lasting, less-frequent and more streamlined.
RenBio's MYO Technology™ is a platform
Make Your Own (MYO) Technology™ is a true platform technology with the flexibility to go beyond traditional treatment paradigms. This is the future in front of your eyes.
Our delivery platform can support virtually any encoded protein product, by varying the DNA blueprints. It also gives the right genetic instructions, encoded in DNA.
MYO Technology™ has broad applicability in the delivery of DNA therapies across a range of
therapeutic areas. Some of these areas include viral diseases, inflammatory diseases and blood and
Furthermore, MYO Technology™ has compelling advantages compared to other novel delivery platforms
when applied to the management of systemic, chronic disease.
Long-lasting delivery of therapeutic proteins can improve treatment of chronic blood disorders.
Monoclonal antibodies are a critical class of drugs for treatment of diseases with this origin.
Anyone can prevent viral infections by the prophylactic use of antiviral antibodies. Their delivery with Make Your Own (MYO) Technology™ would provide lasting protection.